<DOC>
	<DOCNO>NCT00412503</DOCNO>
	<brief_summary>Long term survival achieve 75 % case pediatric cancer . However , type tumor ( ie CNS tumor ) advance stage ( metastatic sarcomas/neuroblastomas ) cure treatment . Thus , evaluation new drug combination strongly need . The recommended dos define child TMZ ( 200 mg/m2/d x 5 ) TPT ( 1.5 mg/m2/d x 5 ) . Some preclinical clinical study show activity drug pediatric cancer . Nevertheless , association two drug never evaluate . The study aim determine Maximum Tolerated Dose dose limit toxicity drug associate assess efficacy combination .</brief_summary>
	<brief_title>Temozolomide Association With Topotecan Refractory Relapsed Malignant Tumors Children Adolescents</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<criteria>histologically document malignant tumor refractory relapse conventional treatment curative treatment available life expectancy &gt; 8 week significant comorbidity ( NCICTC &lt; 2 ) No organ toxicity chemotherapy within 4 previous week , 6 week nitrosurea radiotherapy Hypersensibility Topotecan and/or Temozolomide one compound Hypersensibility Dacarbazine ( DTIC ) Galactosaemia , Glucose galactose malabsorption syndrom , deficiency lactase</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>August 2009</verification_date>
</DOC>